Figure 5.

Anti-tumor Effect of VEGF-siRNA Dry Powder in LLC Lung Metastasis Model

Mice with lung metastases were treated with an intratracheal administration of VEGF-siRNA dry powder or non-target siRNA on days 4, 8, and 11 (n = 4/group). (A and B) The number of tumor nodules on the lung surface was counted 14 days after injection of LLC cells. Bars denote the median values. (C and D) H&E-stained sections from each mouse treated with VEGF-siRNA or non-target siRNA were randomly selected; the ratio of tumor/whole-lung tissue area (%) was calculated using an image analyzing system. p was determined using the Wilcoxon rank-sum test. *p < 0.05 between two groups.